Radiotherapy with immunotherapy and chemotherapy for liver metastases from lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding radiotherapy to immunotherapy and chemotherapy can help people whose lung cancer has spread to the liver and who have already tried standard treatments. It aims to see if this combination is safe and works better at shrinking tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have lung cancer (NSCLC or small cell) that has spread to the liver and has at least one tumor that can be measured on a scan.
- You must have already had chemotherapy and immunotherapy (PD-1/PD-L1 inhibitor) that stopped working or caused unacceptable side effects.
- Your liver function must be adequate (Child-Pugh class A or B), and your blood counts and kidney function must meet specific levels.
- You must be willing to give blood and tissue samples for testing.
- You must not have certain medical conditions like active autoimmune disease, cirrhosis, or severe heart problems, and you must not have had prior liver radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
This trial tests whether giving low-dose radiation to liver tumors along with immunotherapy can help people with certain advanced cancers that have spread to the liver. It may improve how well the treatment works for people whose cancer has stopped responding to earlier treatments.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.